CN1482136A - Extract of american ginseng fruit saponin, extracting and refining method and medicinal use thereof - Google Patents
Extract of american ginseng fruit saponin, extracting and refining method and medicinal use thereof Download PDFInfo
- Publication number
- CN1482136A CN1482136A CNA03127613XA CN03127613A CN1482136A CN 1482136 A CN1482136 A CN 1482136A CN A03127613X A CNA03127613X A CN A03127613XA CN 03127613 A CN03127613 A CN 03127613A CN 1482136 A CN1482136 A CN 1482136A
- Authority
- CN
- China
- Prior art keywords
- panacis quinquefolii
- group
- fructus panacis
- fructus
- total saponins
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Steroid Compounds (AREA)
Abstract
The present invention belongs to the field of medicine, and is especially American ginseng fruit general saponin extractive and its refining process and medicinal use. American ginseng fruit general saponin is extracted with American ginseng fruit as material and through scientific extracting process, and then refined through macroporous resin absorption to obtain American ginseng fruit general saponin product with American ginseng fruit general saponin content of 55-65 %. The product is especially suitable for use in preparing medicine for coronary heart disease, myocardial ischemia, arrhythmia, type-II diabetes and other diseases.
Description
Technical field
The present invention relates to obtain the Fructus Panacis Quinquefolii total saponin extracts its preparation method and contain the pharmaceutical composition of these extracts by extracting Radix Panacis Quinquefolii pulp effective constituent.
Background technology
Fructus Panacis Quinquefolii is the Radix Panacis Quinquefolii mellow fruit.Radix Panacis Quinquefolii (panax quinquefolium L.) claim Radix Panacis Quinquefolii, U.S.'s genseng, panacis quinquefolii radix etc. again, is the araliaceae ginseng plant, originates in the U.S., Canada.Radix Panacis Quinquefolii flavor sweet, little hardship, cool in nature can tonifying spleen be fallen fire, the enriching yin of promoting the production of body fluid, relieving restlessness be tired, and is empty and have fiery person suitable.China has carried out commerial growing on North China, northeast and other places to Radix Panacis Quinquefolii since 1975, and succeeds.Put down in writing the branch that Radix Panacis Quinquefolii has single stem, two stem and many stems according to data, can tie 10-30 fruit on each stem that 3-4 gives birth to, output is higher.
The theoretical basis of the extraction of Fructus Panacis Quinquefolii total saponins PQFS, separate design and the purposes aspect medicine is: this seminar is through for many years to Fructus Panacis Quinquefolii chemical ingredients and bioactive result of study thereof.Utilize advanced extraction, separation and identification of means, from Fructus Panacis Quinquefolii, separate and identified 26 compounds, 23 triterpenoid saponins wherein, comprise 4 newfound compounds, respectively called after Radix Panacis Quinquefolii saponin-F1 ,-F2 ,-F3 and-F4, other be ginsenoside-Ra1 ,-Ra2 ,-Rb1 ,-Rb2 ,-Rb3 ,-Rc ,-Rd ,-Re ,-Rg1 ,-Rg2 ,-Rg3 (R, S) ,-Rh1 ,-Rh2, pseudoginsenoside-F11 and RT5; A new trisaccharide and 2 known compounds.Extraction, process for purification to its total saponins carried out a large amount of research simultaneously, obtained to possess the Fructus Panacis Quinquefolii total saponin extracts of turnout.Show to have stronger treatment coronary heart disease, myocardial ischemia and the arrhythmia and the biological function of treatment type ii diabetes through pharmacology activity research to the Fructus Panacis Quinquefolii total saponins.
Summary of the invention
The invention provides a kind of Fructus Panacis Quinquefolii total saponin extracts, it is characterized by light yellow to brown, Powdered, bitter, UV spectrum (methyl alcohol) has maximum absorption band at the 203nm place, HPLC spectrum demonstrates the peak more than 5, and the content of this Fructus Panacis Quinquefolii total saponin extracts accounts for the heavy 15%-20% of Fructus Panacis Quinquefolii jerky.
The invention still further relates to the method for preparing the said extracted thing, it comprises the steps:
(1) Radix Panacis Quinquefolii pulp is added water at normal temperatures, mechanical stirring, 100 γ pm extract 2-3 time, extract 1-3 hour at every turn;
(2) solution with each time poach gained merges, and filters filtrate for later use;
(3) above-mentioned filtrate is crossed macroporous adsorbent resin, use the 10%-20% washing with alcohol then,, abandon or adopt washing lotion, continue, collect this time elutriant with the 50%-95% ethanol elution near colourless;
(4) with behind this elutriant recovery ethanol, concentrate, drying gets the Fructus Panacis Quinquefolii total saponin extracts.
The invention still further relates to and contain the pharmaceutical composition of Fructus Panacis Quinquefolii total saponin extracts, specifically, the present invention relates to contain the pharmaceutical composition owing to treatment coronary heart disease, myocardial ischemia and arrhythmia and type ii diabetes of this extract as activeconstituents.
Product of the present invention or extract can be made into tablet, soft or glutoid capsule by suitable mode, be used to prepare the ready to use solution that adapts with its solubleness or the granulated powders and the injection liquid of liquid.The dosage of Fructus Panacis Quinquefolii total saponin extracts of the present invention can be administered once or repeatedly in the scope of 30mg-400mg every day, preferred 200mg, and administration every day 2 times, suitable form of administration is an oral dosage form.
Characteristics of the present invention and beneficial effect are: in the drug regimen of treatment cardiovascular disorder and diabetes, effect is obvious as new medicinal efficient part for the Fructus Panacis Quinquefolii total saponin extracts, and toxic side effect is little, the curative ratio height; The Fructus Panacis Quinquefolii aboundresources, preparation technology's method that the present invention adopts, simple, be fit to suitability for industrialized production, the yield height of total saponins has broad application prospects.
The concrete scheme of extracting, making with extra care the Fructus Panacis Quinquefolii total saponins among the present invention is: a. extracts: with the sophisticated Fructus Panacis Quinquefolii of Araliaceae Panax is raw material, after removing seed, collection pulp, fruit juice are test raw material, the water that adopts the most cheap economy is as extracting solvent, because it is bigger that glassware for drinking water has been equipped with the solubleness of Fructus Panacis Quinquefolii total saponins, boiling point is higher, and safety is non-environmental-pollution again, advantages such as easy recovery.
The mechanical stirring mode is carried out, adopted to the said extracted process at normal temperatures, and 100 γ pm accelerate to extract, with a certain amount of Radix Panacis Quinquefolii pulp or juice water with 3 times of amounts, extract respectively 3 times, filter united extraction liquid, concentrating under reduced pressure, 0.07Mpa, to flowing paste, proportion 1.11-1.21, get the thick product of Fructus Panacis Quinquefolii total saponins, cryopreservation.B. refining: it is a certain amount of to get Fructus Panacis Quinquefolii total saponins crude product, the water dilution of 5 times of amounts of water, macroporous adsorbent resin D101 on the diluent, at first water is eluted to colourless, use the 10%-20% ethanol elution to colourless then, use the 70%-85% ethanol elution at last, collect last elutriant, reclaim eluent and get the Fructus Panacis Quinquefolii total saponins, productive rate 10%-20%.Purity contains Fructus Panacis Quinquefolii total saponins 55%-65%.
The advantage of extraction of the present invention, process for purification is to be raw material with the Fructus Panacis Quinquefolii, at normal temperatures and pressures, is that solvent extracts the thick product of Fructus Panacis Quinquefolii total saponins with water; And then make with extra care with macroporous adsorbent resin, method is simple, does not need other deleterious organic solvent, and the yield height has reached the purity of drug manufacture.
The Fructus Panacis Quinquefolii total saponins has the pharmacologically active for the treatment of cardiovascular disorder, type ii diabetes preferably, the type ii diabetes traditional Chinese medical science is referred to as diabetes, belong to type of deficiency of both QI and YIN, thereby the Fructus Panacis Quinquefolii total saponins can be used for preparing medicine, be specially adapted to treat coronary heart disease, myocardial ischemia, arrhythmia; Diseases such as treatment diabetes.
In order to prepare medicine with the Fructus Panacis Quinquefolii total saponins, be made into a kind of pharmaceutical preparation of form, said preparation also has the vehicle of solid or liquid except that activeconstituents.The formulation of medication and administration is normally such, and under the situation for oral administration, it can any conventionally form administration, as powder, granula, tablet, capsule, pill etc., and solution such as suspension agent, syrup etc., buccal tablets, sublingual lozenge etc.Here the vehicle of solid of Shi Yonging or liquid is being known in the art.
Medicines such as Fructus Panacis Quinquefolii total saponins preparation treatment coronary heart disease, myocardial ischemia, arrhythmia, diabetes are to be made of effective constituent monomer or the effective constituent vehicle with solid or liquid.Below for several concrete examples: powder is if powder agent for oral administration, its vehicle has lactose, starch, paste essence, lime carbonate, calcium phosphate, synthetic or natural pure aluminium silicate, magnesium oxide, anhydrous alumina, Magnesium Stearate, sodium bicarbonate, dry yeast etc., and its formulation comprises electuary, tablet, capsule etc.; The vehicle of solution has water, glycerine, propylene glycol, simple syrup, ethanol, fatty oil, ethylene glycol, polyoxyethylene glycol, Sorbitol Powder, Xylitol etc.;
The dosage of active substance can change according to the mode of taking, patient's age, body weight and be in a bad way degree and other similar factors.Daily dosage portion is: oral 200mg-300mg, divide secondary to take.
With treatment coronary heart disease, myocardial ischemia, arrhythmia, the diabetes medicament of Fructus Panacis Quinquefolii total saponins preparation, its advantage is good effect, have no side effect, cheap etc.
The present invention further specifies by following experiment.2. pharmaceutical use 2.1 Fructus Panacis Quinquefolii total saponins (PQFS) of the present invention are to the influence of dog Acute Myocardial Infarction
Purpose: observe of the influence of Fructus Panacis Quinquefolii total saponins to the experimental myocardial infarction of hybrid dog.Method: adopt the branch of coronary artery ligation method, cause Acute Myocardial Infarction.Give Fructus Panacis Quinquefolii total saponins 1,2,4mg/kg, verapamil 0.2mg/kg, iv, observe hemodynamic index and vim and vigour index, comprising: electrocardiogram(ECG ECG, calculate heart rate HR, blood pressure BP, left indoor pressure LVSP, left side chamber end-diastolic pressure LVEDP, maximum rate of change ± the dp/dt of left indoor pressure, coronary flow CBF, cardiac output Co, art pO2, the vein oxygen partial pressure, arterial oxygen saturation, Svo2 and secondary data: myocardial blood flow MBF, cardiac output SV, cardiac index CI, SI SI, left side chamber work done, coronary resistance CVR, total peripheral resistance TPVR, myocardial consumption of oxygen, the myocardial oxygen consumption index, cardiac muscle coefficient of oxygen utilization %, arterial oxygen content, venous oxygen content; Measure epicardial electrogram EECG, myocardial infarct size N-ST calculating myocardium infraction degree ∑-ST; Detect serum creatine kinase CK, lactate dehydrogenase L DH, aspartate amino transferase AST; The myocardial infarction area of weighing accounts for and reaches left ventricular mass % whole-heartedly.The result: the Fructus Panacis Quinquefolii total saponins can obviously increase CBF, Co, MBF, CI, SI, blood oxygen saturation; Remarkable minimizing+dp/dt, SV, CVR; Reduce myocardial ischemia scope and degree of ischemia, Serum LDH, AST content descend, and dwindle myocardial infarction area.Conclusion: the Fructus Panacis Quinquefolii total saponins can alleviate the damage of myocardial ischemia, and heart is had provide protection.2.1.1 experiment material 2.1.1.1 medicine Fructus Panacis Quinquefolii total saponins is provided by chemistry teaching and research room of preclinical medicine institute of Jilin University, white powder is mixed with desired concn with physiological water before the test.Verapamil Injection, Shanghai Hefeng Pharmaceutical Co., Ltd. produces, product batch number: 990401.Vetanarcol, Shanghai chemical reagent packing factory, lot number: 84-06-12.Advance chemical chemical reagent work of chlorination nitro tetrazole orchid, Shanghai produces lot number: 20000502.Lidocaine hydrochloride injection, The 2nd Army Medical College morning sunlight pharmaceutical factory in Shanghai produces, lot number: 990405.
Biochemical reagents aspartate amino transferase AST test kit, creatine kinase CK test kit, lactate dehydrogenase L DH test kit is produced lot number: 20010501 by all living creatures' health biotechnology development centre, Beijing.2.1.1.2 animal hybrid dog, body weight 10kg-17kg is provided by laboratory animal portion of Jilin University.2.1.1.3 instrument RM-6000 type polygraph, MFV-3200 type magnetic flow meter is produced by Japanese photoelectricity company.The semi-automatic seralyzer of EOS880 type, Italy produces, and the Corning158 Bloodgas Analyzer is produced in USA.The SC-3 electric pulmotor, Shanghai Medical Equipment Factory produces.2.1.2 experimental technique
30 of healthy hybrid dogs are divided into 5 groups at random, and 6 every group, with the anesthesia of 30mg/kg Sodital sodium solution, iv.Back of the body position is fixing, cuts skin of neck with cauter, separates tracheae and carries out trachea cannula, connects the breathing apparatus, malleation 2-3kPa; Separate left carotid, intubate connects pressure transducer, measures arteriotony (BP); Separate right common femoral artery, insert ventricular catheter, connect pressure transducer, record LVSP, through coupling amplifier pa, record LVEDP is through differential processor for recording ± dp/dt; Separate the right lateral thigh vein in order to administrable; It is subcutaneous to thrust four limbs with needle electrode, and record mark II lead electrocardiogram (ECG) is calculated heart rate (HR).
The dog right arm reclining is opened chest along breastbone left side the 4th intercostal, removes the 4th rib, retract rib with rib retractor, expose heart, pericardium is mentioned make the pericardium bed, separate aortic root, place suitable magnetic flow meter probe, measuring the aorta flow is cardiac output Co; Separate 1/3 place under the anterior descending coronary, be equipped with line and treat ligation usefulness; Separate LCA, place suitable magnetic flow meter probe, measure coronary flow CBF; With wet cloth formula electrode, measure epicardial electrogram EECG.Write down 24 points, a bit place normal district, all the other 23 are positioned over infraction marginarium and infraction central section respectively.
Operation finishes, and stablizes 10 minutes.Write down every index of normal blood flow kinetics and EECG then; Get artery A blood and vein V blood and survey the vim and vigour value, get V blood 5ml carry out centrifugal, separation of serum, test serum creatine kinase CK, lactate dehydrogenase L DH and aspartic acid transferring enzyme AST.
Iv Xylotox before the ligation prevents irregular pulse.1/3 place under the ligation branch of coronary artery then, EECG is not obvious as myocardial ischemia, 1/2 place of ligation branch of coronary artery again causes myocardial infarction and ischemia model, record during myocardial ischemia and after the administration 5,10,20,30,45,60,90,120,150,180, the every index of 240min haemodynamics; Behind record myocardial ischemia and the medicine 5,10,20,30,45,60,90,120,180,240,300,360minEECG changes.With ST section total mv number that raises, ∑-ST represents degree of myocardial ischemia, with the ST section raise 〉=numerical table that leads of 2mv shows myocardial ischemia scope, N-ST; Detect behind myocardial ischemia, the medicine 60,120,180, the serum cardiac muscle three enzyme content of 240min vim and vigour value and myocardial ischemia 6h; Experiment finishes to win heart and claims heavy whole-heartedly; Along coronary sulcus excision atrium, claim left chamber heavy.Parallel shape is cut into the thick myocardium sheet of 1cm with ventricle then, cuts the 1cm of 1cm place cardiac muscular tissue under the ligature
3, it is fixing to put into 10% formalin solution, does the light microscopic check pathological section; Myocardium sheet is put into the blue solution of 0.1% chlorination nitro tetrazole to dye, incubate about 10 minutes in 37 degree water bath with thermostatic control temperature, taking-up is inhaled the branch that anhydrates with filter paper, the tissue of non-infarct being dyed blue look cuts off, the infarct cardiac muscular tissue weight of weighing calculates by weighting method that infarcted myocardial tissue accounts for whole-heartedly or the percentage of left ventricular mass.
Haemodynamics one-level data are by formula calculated secondary data, comprise myocardial blood flow, cardiac output, cardiac index, SI, the work done of left chamber, coronary resistance, total peripheral resistance, myocardial consumption of oxygen, myocardial oxygen consumption index, myocardium coefficient of oxygen utilization, artery and venous oxygen content.(X ± s) expression organizes a measured value and changes percentage t check analysis all experimental datas with means standard deviation.2.1.3 experimental result 2.1.3.1 is right ± influence (1) of dp/dt is right+influence of dp/dt
Low dose of 1.0mg/kg, middle dosage group 2.0mg/kg of Fructus Panacis Quinquefolii total saponins be right+and dp/dt do not have obvious influence.The heavy dose of group of Fructus Panacis Quinquefolii total saponins (4.0mg/kg) percentage of 20-180min+dp/dt behind medicine is starkly lower than the saline control group, compares for two groups, and there were significant differences, P＜0.05, P＜0.01.The 5-60min+dp/dt percentage is starkly lower than the saline control group behind the verapamil group medicine, has compared notable difference for two groups, P＜0.05, P＜0.01.(2) influence of right-dp/dt
Fructus Panacis Quinquefolii total saponins small dose group and the right-dp/dt of heavy dose of group do not have obvious influence.And middle dosage group 30min time-dp/dt behind medicine is starkly lower than the saline control group, compares significant difference for two groups, P＜0.05.Verapamil 30min time-dp/dt behind medicine significantly is lower than the saline control group, compares P＜0.05 for two groups.2.1.3.2 influence to CBF
Fructus Panacis Quinquefolii total saponins small dose group 10minCBF behind medicine compares significant difference for two groups, P＜0.05 apparently higher than the saline control group.Dosage group 30minCBF behind medicine is significantly higher than the saline control group in the Fructus Panacis Quinquefolii total saponins, P＜0.05.The heavy dose of group of Fructus Panacis Quinquefolii total saponins 5-45minCBF behind medicine obviously increases P＜0.05.Verapamil group 5-90minCBF behind medicine obviously increases, and compares significant difference, P＜0.05, P＜0.01 with the saline control group.The rising percentage of 20-30minCBF is significantly higher than the saline control group behind its medicine, P＜0.05, P＜0.01.2.1.3.3 influence to Co
Each dosage group of Fructus Panacis Quinquefolii total saponins, Co reduces gradually after the administration, but small dose group Co when 240min still is higher than the saline control group, and two groups of comparing differences are remarkable, P＜0.05.Verapamil group 45minCo behind medicine is starkly lower than the saline control group, compares for two groups, and there were significant differences, P＜0.05.2.1.3.4 influence to MBF
Fructus Panacis Quinquefolii total saponins small dose group does not have obvious influence to MBF.Middle dosage group each time point behind medicine all can increase MBF, and is remarkable with saline control group comparing difference, P＜0.05, P＜0.01.Heavy dose of group 5-45minMBF behind medicine compares for two groups apparently higher than the saline control group, and there were significant differences, P＜0.05.20-30minMBF rising percentage is apparently higher than the saline control group behind the verapamil group medicine, and two groups of comparing differences are remarkable, P＜0.05, and P＜0.01 sees Table 1.
Table 1 PQFS is to myocardial infarction dog myocardial blood flow (ml/100g/min)
-Influence (x ± s, N=6)
Salt solution group verapamil PQFS
0.2mg/kg mg/kg 2mg/kg 4mg/kg
Normal 211.59 ± 41.83 192.24 ± 29.17 200.05 ± 27.74 237.63 ± 36.44 227.10 ± 12.46
0
Infraction 149.90 ± 20.61 147.46 ± 19.58 147.00 ± 19.78 177.23 ± 28.39 167.74 ± 11.47
5 minutes 155.69 ± 15.44 165.09 ± 30.25 156.25 ± 15.02 186.00 ± 24.86
*184.42 ± 22.40
*
％ 4.40±5.48 11.57±9.67 7.21±11.96 5.43±5.52 9.65±6.19
10 minutes 152.11 ± 16.81 167.96 ± 35.84 156.25 ± 15.27 184.17 ± 24.51
*175.96 ± 18.08
*
％ 1.84±4.03 13.16±12.40 7.21±12.03 4.35±4.64 4.71±3.82
20 minutes 154.12 ± 15.84 172.35 ± 32.99 157.27 ± 15.49 186.74 ± 24.74
*178.38 ± 19.03
*
％ 3.33±5.78 16.43±10.74
* 7.86±11.40 5.81±4.41 6.13±4.32
30 minutes 150.54 ± 17.20 173.15 ± 29.10 161.33 ± 20.2 185.39 ± 24.49
*172.93 ± 17.11
*
％ .78±4.52 17.31±9.83
** 10.94±16.83 5.08±4.78 2.92±3.31
45 minutes 155.03 ± 11.78 166.56 ± 31.22 157.94 ± 15.41 198.20 ± 28.80
*187.56 ± 23.14
*
％ 4.39±10.07 13.51±17.76 8.24±10.53 12.20±6.17 11.49±6.82
60 minutes 156.73 ± 13.80 168.22 ± 32.32 155.87 ± 15.27 209.52 ± 40.69
*175.40 ± 19.94
％ 5.46±10.30 14.72±18.97 6.80±10.07 20.51±32.58 4.34±5.39
90 minutes 155.61 ± 16.28 167.52 ± 34.47 156.88 ± 17.37 187.39 ± 30.45
*175.40 ± 19.94
％ 4.75±12.77 14.02±19.04 7.17±7.03 5.79±5.55 4.34±5.39
120 minutes 154.39 ± 19.97 155.44 ± 33.45 153.65 ± 15.35 186.40 ± 26.96
*175.40 ± 19.94
％ 3.24±5.90 5.24±14.84 5.08±6.84 5.44±3.91 4.34±5.39
150 minutes 151.82 ± 17.28 156.72 ± 35.83 153.08 ± 14.99 187.76 ± 29.12
*173.42 ± 18.11
％ 1.83±8.44 6.21±17.43 4.75±7.86 6.12±5.53 3.23±4.93
180 minutes 148.33 ± 13.59 149.83 ± 29.27 151.62 ± 15.85 185.41 ± 26.91
*168.59 ± 22.93
％ -0.32±8.57 1.58±12.93 3.66±7.22 5.02±7.08 0.20±7.78
240 minutes 144.75 ± 14.05 147.17 ± 29.76 141.75 ± 13.00 181.45 ± 28.64
*165.06 ± 23.44
Compare with the saline control group %-2.92 ± 5.38-0.39 ± 12.30-2.93 ± 7.27 2.45 ± 2.78-1.89 ± 8.70
*P＜0.05,
*P＜0.012.1.3.5 is to the influence of SI
Fructus Panacis Quinquefolii total saponins small dose group behind medicine during 240min the decline percentage of SI be starkly lower than the saline control group, two groups of comparing differences are remarkable, P＜0.05.All the other each groups of Fructus Panacis Quinquefolii total saponins do not have obvious influence to SI.The verapamil group does not have obvious influence to SI.2.1.3.6 CVR is influenced
Fructus Panacis Quinquefolii total saponins low dose, heavy dose of group do not have obvious influence to CVR.In the Fructus Panacis Quinquefolii total saponins behind the dosage group medicine 5,20,45,60, many time point CVR of 120-240min obviously reduce, and compare significant difference, P＜0.05 with the saline control group.Verapamil is combined in the decline percentage of 5-45,90minCVR behind the medicine apparently higher than the saline control group, compares significant difference for two groups, P＜0.05, P＜0.01, P＜0.001.2.1.3.7 to the influence (1) of EECG influence to N-ST
Fructus Panacis Quinquefolii total saponins small dose group 45-120min, 360minN-ST after administration are starkly lower than the saline control group, P＜0.05, and it reduces percentage apparently higher than the saline control group, P＜0.05.In dosage group 45-360minN-ST behind medicine be significantly less than the saline control group, compare significant difference for two groups, P＜0.05, the decline percentage of its 20-180,240-360minN-ST is apparently higher than the saline control group, P＜0.05.The heavy dose of group of Fructus Panacis Quinquefolii total saponins 90-180minN-ST behind medicine is bright to be lower than the saline control group, P＜0.05, and it reduces percentage apparently higher than the saline control group, compares significant difference with the saline control group, P＜0.05.Verapamil group 45min, 90-360minN-ST behind medicine are significantly less than the saline control group, compare significant difference for two groups, P＜0.05, P＜0.01.The reduction percentage of its 45-360minN-ST is apparently higher than the saline control group, P＜0.05.(2) to the influence of ∑-ST
Fructus Panacis Quinquefolii total saponins low dose 90min ∑-ST behind medicine obviously is lighter than the saline control group, and two groups of comparing differences are remarkable, P＜0.05, its decline percentage of 20-120min is apparently higher than the saline control group behind the medicine, two groups relatively there were significant differences, P＜0.05, P＜0.01.Dosage group 90-120min ∑-ST behind medicine significantly is lighter than the saline control group in the Fructus Panacis Quinquefolii total saponins, P＜0.01, P＜0.05, behind the medicine decline percentage of 20-360min ∑-ST apparently higher than the saline control group, P＜0.05, P＜0.01.60-360min ∑-ST behind medicine is lighter than salt solution group for the heavy dose of group of Fructus Panacis Quinquefolii total saponins, and its decline percentage is apparently higher than the saline control group, P＜0.05, P＜0.01.60-360min ∑-ST obviously is lighter than the saline control group behind the verapamil group medicine, compares with the saline control group that there were significant differences, P＜0.05, P＜0.01, the reduction percentage of 10-360min ∑-ST is apparently higher than saline control group P＜0.05, P＜0.01 behind the medicine, P＜0.001 sees Table 2.
Table 2 PQFS to myocardial infarction dog degree of ischemia (influence of ∑-STmv) (and x ± s, N=6)
Salt solution group verapamil PQFS
0.2mg/kg 1.0mg/kg 2.0mg/kg 4.0mg/kg
Normal 18.25 ± 11.88 29.92 ± 6.14 23.75 ± 7.15 20.08 ± 8.95 27.17 ± 5.06
Infraction 139.83 ± 38.15 164.42 ± 47.95 138.83 ± 22.32 157.17 ± 22.21 131.83 ± 24.94
5 minutes 118.59 ± 29.75 105.92 ± 42.61 98.92 ± 25.83 118.83 ± 27.17 99.92 ± 21.82
％ -10.50±29.48 -36.78±10.90 -29.22±12.06 -24.78±9.91 -24.34±7.65
10 minutes 107.00 ± 13.62 89.00 ± 34.76 99.42 ± 26.10 113.17 ± 21.85 98.00 ± 17.36
％ -19.33±21.19 -45.83±13.74
* -28.15±15.14 -27.94±9.94 -24.65±13.83
20 minutes 112.08 ± 20.70 77.25 ± 36.13 87.88 ± 24.94 96.33 ± 27.39 92.42 ± 1.10
％ -17.30±14.26 -54.23±12.14
*** -37.26±11.14
* -38.38±17.45
* -29.21±10.46
30 minutes 109.42 ± 20.59 87.92 ± 37.09 85.92 ± 35.74 94.50 ± 21.74 80.83 ± 23.87
％ -19.34±13.23 -47.72±11.73
** 39.84±17.28
* -39.04±16.53
* -37.82±20.49
45 minutes 112.92 ± 22.98 85.58 ± 30.59 83.33 ± 36.86 85.33 ± 22.75 82.50 ± 30.42
％ -15.96±20.18 -47.69±13.86
** -41.91±18.73
* -44.87±15.90
* -36.39±26.17
60 minutes 109.42 ± 34.02 70.58 ± 24.47
*75.42 ± 16.62 76.25 ± 22.65 69.25 ± 22.75
*
％ -20.34±17.83 -56.49±11.90
** -45.61±10.01
* -49.51±14.33
* -46.65±19.14
*
90 minutes 120.83 ± 25.20 62.92 ± 15.28
* *78.50 ± 25.60
*74.00 ± 22.08
*67.17 ± 19.48
*
％ -9.18±25.92 -58.92±15.75
** -43.95±14.80
* -51.82±16.69
**?-49.40±9.68
**
120 minutes 114.08 ± 31.18 68.50 ± 13.51
*82.58 ± 15.98 72.50 ± 20.68
*65.33 ± 29.69
*
％ -17.55±12.46 -56.92±9.53
*** -40.26±9.46
** -52.98±15.01
**?-52.14±11.05
***
150 minutes 109.92 ± 38.44 57.38 ± 14.50
*79.83 ± 27.75 74.25 ± 19.07 62.83 ± 21.55
*
％ -20.53±17.97 -62.32±15.06
** -42.33±18.30 -52.04±13.54
**?-53.24±7.52
**
180 minutes 101.67 ± 32.36 52.42 ± 14.92
*90.00 ± 26.65 76.25 ± 18.97 58.50 ± 21.59
*
％ -24.92±22.52 -67.21±7.88
** -34.52±17.92 -50.64±15.23
* -56.63±8.81
**
240 minutes 99.75 ± 26.21 58.83 ± 24.45
*76.25 ± 15.83 77.92 ± 25.91 57.08 ± 20.14
*
％ -26.43±17.08 -63.78±11.56
** -44.53±10.59 -49.83±18.24
* -57.33±10.97
**
300 minutes 101.33 ± 34.20 53.67 ± 22.66
*81.42 ± 34.92 66.42 ± 33.50 63.25 ± 24.02
*
%-27.80 ± 9.93-67.03 ± 10.05
* *-41.54 ± 20.74-56.10 ± 24.56
*-53.00 ± 12.06
*Compare with the saline control group
*P＜0.05,
*P＜0.01,
* *P＜0.001.2.1.3.8 is to the influence of seroenzyme
AST is starkly lower than the saline control group after the administration of Fructus Panacis Quinquefolii total saponins small dose group, compare for two groups, and significant difference, P＜0.05 does not have obvious influence to CK, LDH.In the Fructus Panacis Quinquefolii total saponins after the administration of dosage group LDH content obviously reduce, its decline percentage is starkly lower than the saline control group, P＜0.05, its AST, CK value and salt solution group relatively do not have significant difference.Fructus Panacis Quinquefolii total saponins heavy dose of group AST and LDH content decline percentage are starkly lower than the saline control group, P＜0.05, P＜0.01.AST, LDH content significantly descend after the administration of verapamil group, and its decline percentage is starkly lower than the saline control group, compare significant difference, P＜0.05, P＜0.01 for two groups.2.1.3.9 influence to myocardial infarction area
Fructus Panacis Quinquefolii total saponins small dose group cardiac muscle heart stalk weight accounts for heavy whole-heartedly % and is starkly lower than the saline control group, compares significant difference, P＜0.05 for two groups.Dosage in the Fructus Panacis Quinquefolii total saponins, heavy dose of group heart stalk area account for whole-heartedly, the heavy % in left chamber all is starkly lower than the saline control group, the highly significant meaning are arranged, P＜0.05, P＜0.01.Heart stalk weight accounts for whole-heartedly after the administration of verapamil group, left ventricular mass % all is starkly lower than the saline control group, compare for two groups, and significant difference, P＜0.05, P＜0.01 sees Table 3.
Table 3 PQFS is to the influence (x ± s N=± 6) of myocardial infarction dog infarct size
Salt solution group verapamil PQFS
0.2mg/kg 1mg/kg 2mg/kg 4mg/kg
Account for % 7.97 ± 1.494 4.65 ± 2.12 whole-heartedly
*3.25 ± 1.79
*6.05 ± 0.63
*4.22 ± 1.85
*
Account for left heart % 10.54 ± 2.07 5.48 ± 1.77
*7.58 ± 5.15 8.10 ± 0.89
*5.82 ± 2.45
*Compare with the saline control group
*P＜0.05,
*P＜0.012.1.3.10 is to the influence of myocardial infarction pathological section
Saline control group myocardial infarction pathology more obviously, heavier, and positive drug group and administration group pathology all have than the salt solution group and obviously alleviate, especially heavy dose of group pathology is the lightest, illustrate that this medical instrument has certain function of resisting myocardial ischemia, and dosage is big more, effect is obvious more.2.1.4 experiment conclusion
The Fructus Panacis Quinquefolii total saponins can alleviate treating myocardial ischemia damage, increases blood supply of cardiac muscle, and heart is had provide protection, is suitable for cardiovascular system diseases such as treatment myocardial ischemia, coronary heart disease and arrhythmia.2.2 the Fructus Panacis Quinquefolii total saponins is to the influence of Wistar rat zoic model with hyperglycemia
Large, medium and small three the dosage groups of Fructus Panacis Quinquefolii total saponins 0.52g/kg, 0.26g/kg, 0.13g/kg (be equivalent to respectively clinical equivalent consumption 8 times, 4 times, 2 times), wherein big or middle dosage group can make Wistar rat zoic model with hyperglycemia glucose level descend, has obvious statistical significance P＜0.05, with diabetes pill group 2.0g/kg, be equivalent to 4 times of clinical equivalent consumption, have similar effect; Can make the whole blood height cut the low specific viscosity of cutting of specific viscosity, whole blood and descend, relatively have obvious statistical significance P＜0.05 with model group, P＜0.01, big or middle dosage group can make plasma viscosity obviously descend, and relatively has obvious statistical significance P＜0.05 with model group.
Fructus Panacis Quinquefolii total saponins 0.90g/kg, 0.45g/kg, 0.09g/kg, be equivalent to 10 times, 5 times, 1 times of clinical equivalent consumption respectively, the Kunming mouse glucose tolerance curve is influenced test-results to be shown, give behind the glucose 30 minutes, the heavy dose of group of Fructus Panacis Quinquefolii total saponins blood glucose value descends and model group relatively has notable difference P＜0.05, all the other each administration group blood glucose values are lower than model group, but not statistically significant.Gave glucose 60 minutes, each is organized blood glucose value and obviously raises, and wherein each group of Fructus Panacis Quinquefolii total saponins and diabetes pill group blood glucose value are lower than model group, but not statistically significant P＞0.05 is respectively organized blood glucose value in the time of can 120 minutes and all recovered normal.2.2.1 test materials
Medicine Fructus Panacis Quinquefolii total saponins provides lot number by preclinical medicine institute of Jilin University natural drug research department: 20000708; Diabetes pill is by Guangzhou No.1 Chinese Pharmacy Factory production, authentication code: (1994) No. 11146, and the patent No.: ZL953081990.
Animal wistar rat, male and female half and half, body weight 195g-245g is provided by laboratory animal portion of Jilin University, the certification of fitness number: the moving word of doctor 10-5110 number; Main agents and instrument U-9889 (STZ) U.S. sigma chemical company produce, lot number: 89H0604 blood sugar strip Yicheng Biological Electronic Technology Co., Ltd., Beijing produces.JPS-III type rapid blood sugar test instrument Yicheng Biological Electronic Technology Co., Ltd., Beijing produces.Whizzer Beijing Medical Centrifugal Machine Factory, model: LDZ5-2.Full automatic biochemical apparatus HIT produces, model: the 7170A of Hitachi type.2.2.2 test method
After animal portion of Jilin University introduces the Wistar rat, raise in animal housing of preclinical medicine institute of Jilin University, room temperature 22-25 ℃, humidity 30-60%, feed is formed: Semen Maydis powder 39%, soya-bean cake face 25%, wheat bran face 14%, sorghum meal 10%, bone meal 2.5%, fish meal 5%, yeast 3.5%, additive 1%.
Get the confession reagent liquid that Fructus Panacis Quinquefolii total saponins medicinal powder is made into 5.2% (g/v), 2.6% (g/v), large, medium and small three dosage of 1.3% (g/v).It is 20% (g/v) test liquid that diabetes pill is made into concentration.
Introduce 106 of Wistar rats from animal portion of Jilin University, male and female half and half adapted to for 1 week in this chamber, and fasting be can't help water after 4 hours, weighed, surveyed blood sugar, marks.Select blood glucose value in normal range, the rat of 100 male and female half and half that state is good cooked experiment, therefrom stay 10 as the normal control group, 90 Wistar rats are pressed 0.054g/kg modeling type with U-9889 STZ, and U-9889 STZ is made into 2.0% solution with 0.05mol/L citric acid solution PH=4.5.The rat fasting can't help water 16 little to after, once inject U-9889 STZ soup by the body weight abdominal cavity.Fasting in the 8th day be can't help water after 4 hours, surveyed blood sugar, and wherein blood glucose value is that model is set up greater than 10mmol/L.With the normal control group significant difference is arranged relatively, P＜0.001.With 54 hyperglycemia model animals, the marrow machine is divided into five groups, and 10～11 every group, each group of male and female is divided equally.Be grouped into: normal control group, model group, diabetes pill group 2.0g/kg, be equivalent to 4 times of clinical consumption, the heavy dose of group of Fructus Panacis Quinquefolii total saponins 0.52g/kg, middle dosage group 0.26g/kg, small dose group 0.13g/kg, be equivalent to 8,4,2 times of clinical consumption.
Model group feedwater 10ml/kg, each administration group all gives 10ml/kg for reagent liquid.Gastric infusion about at 9 o'clock in morning every day, continuously around, survey blood sugar, body weight weekly, calculate dose once by new body weight.In administration back execution all around animal, get blood and survey routine blood test, blood parameters, hemorheology and insulin content, and get pancreas and carry out histopathologic examination.Each group gained result is represented that with average x ± standard deviation S result and model group are organized a t check, judge its significance.2.2.3 test-results 2.2.3.1 is to the influence of blood sugar
The heavy dose of group of the 3rd all Fructus Panacis Quinquefolii total saponins and model group comparison blood sugar obviously descend (P＜0.05) after the administration.Big or middle dosage group of Fructus Panacis Quinquefolii total saponins and diabetes pill group blood glucose value all reduce around, with model group relatively, have obvious statistical significance, P＜0.05 sees Table 4.
Table 4 Fructus Panacis Quinquefolii total saponins is to the influence of hyperglycemia model rat blood sugar value (mmol/L) (x ± s)
Dosage group small dose group in the heavy dose of group of group normal control group model group diabetes pill group
Dosage 10ml/kg 2.0g/kg 0.52g/kg 0.26g/kg 0.13g/kg
Animal (only) 10 89 10 98
Administration preceding 6.12 ± 0.53 17.52 ± 2.40 17.22 ± 3.22 17.04 ± 3.34 17.10 ± 2.63 16.37 ± 3.32
One week 6.19 ± 0.55 17.15 ± 2.23 16.85 ± 3.06 15.54 ± 3.23 15.10 ± 2.36 15.72 ± 3.10
Two weeks 6.12 ± 0.41 15.85 ± 3.02 14.57 ± 3.02 13.57 ± 2.60 14.06 ± 2.53 15.12 ± 3.23
Three weeks 6.12 ± 0.31 14.09 ± 3.52 11.97 ± 2.53 10.93 ± 2.58* 11.71 ± 2.72 13.05 ± 3.26
5.85 ± 0.46 13.80 ± 4.12 9.36 ± 2.83*, 9.07 ± 2.78*, 9.49 ± 1.98* 11.81 ± 3.63 compare with model group all around, and * P＜0.052.2.3.2 is to the influence of blood parameters
The blood glucose value and the model group of big or middle dosage group of Fructus Panacis Quinquefolii total saponins and diabetes pill group more all have obvious decline, has statistical significance (P＜0.05), the total protein (TP) of diabetes pill group, heavy dose of group relatively has obvious rising with model group, has statistical significance (P＜0.01), the blood urea nitrogen BUN and the model group of the heavy dose of group of Fructus Panacis Quinquefolii total saponins relatively decrease, have statistical significance (P＜0.05), see Table 5.
Table 5 Fructus Panacis Quinquefolii total saponins is to the influence of diabetes rat biochemical indicator (x ± s)
Dosage group small dose group in the heavy dose of group of group normal control group model group diabetes pill group
Dosage 10ml/kg 2.0g/kg 0.52g/kg 0.26g/kg 0.13g/kg
Animal (only) 10 89 10 98
ALT(U/L) 42.7±20.2 101.0±32.6 112.6±58.8 100.9±55.2 108.2±45.9 133.5±85.4
AST(U/L) 87.1±27.3 157.5±49.2 163.8±66.2 171.9±97.5 187.7±81.9 215.4±133.0
ALP(U/L) 204.3±139.0 532.4±156.1 600.1±256.9 390.0±181.9?530.1±234.4 669.4±201.9
TP(g/L) 62.3±4.1 61.2±3.5 66.7±2.5** 66.4±3.3** 64.6±3.5 62.9±6.1
ALB(g/L) 34.5±3.5 30.2±2.4 31.2±1.8 33.7±4.1 32.3±2.4 32.9±2.0
TBIL(umol/L) 0.37±0.23 0.39±0.34 0.17±0.11 0.36±0.32 0.24±0.20 0.45±0.43
BUN(mmol/L) 8.1±0.8 11.2±4.5 8.9±1.0 7.5±1.6* 8.8±0.9 8.8±1.6
CRE2(umol/L) 58.5±4.7 82.5±29.5 69.8±7.7 64.4±4.8 66.1±5.8 68.3±6.7
CLU(mmol/L) 6.07±1.82 13.98±4.94 9.33±3.29* 8.68±2.78* 9.27±2.76* 11.58±3.82
CHO (mmol/L) 1.3 ± 0.2 1.4 ± 0.5 1.2 ± 0.2 1.4 ± 0.4 1.2 ± 0.1 1.2 ± 0.1 compares * P＜0.05, * * P＜0.012.4 experiment conclusion with model group
Fructus Panacis Quinquefolii total saponins PQFS has the biological activity that reduces the rat experiment diabetes.
Embodiment Fructus Panacis Quinquefolii total saponins of the present invention extracts, process for purification
Embodiment one:
A. extraction: get 1.0kg Radix Panacis Quinquefolii pulp, be dissolved in the 3L water, at room temperature, stir, 100 γ pm extract 2h, extract 3 times, filter, and merge filtered solution, and 0.07Mpa is evaporated to certain volume, and density 1.102 gets Fructus Panacis Quinquefolii total saponins crude product;
B. refining: get thick Fructus Panacis Quinquefolii total saponins, last macroporous adsorbent resin D101 washes with water earlier to colourless, uses 10% ethanol elution instead to colourless, uses 95% ethanol elution at last, collects elutriant, be recycled to dried, must Fructus Panacis Quinquefolii total saponins product, productive rate 20%.
Embodiment two:
A. extraction: get 1.0kg Radix Panacis Quinquefolii pulp, be dissolved in the 3L water, at room temperature, stir, 100 γ pm extract 3h, extract 2 times, filter, and merge filtered solution, and 0.07Mpa is evaporated to certain volume, and density 1.192 gets Fructus Panacis Quinquefolii total saponins crude product;
B. refining: get thick Fructus Panacis Quinquefolii total saponins, last macroporous adsorbent resin D4020 washes with water earlier to colourless, uses 15% ethanol elution instead to colourless, uses 75% ethanol elution at last, collects elutriant, be recycled to dried, must Fructus Panacis Quinquefolii total saponins product, productive rate 15%.
Embodiment three:
A. extraction: get 1.0kg Radix Panacis Quinquefolii pulp, be dissolved in the 3L water, at room temperature, stir, 100 γ pm extract 3h, extract 2 times, filter, and merge filtered solution, and concentrating under reduced pressure (0.07Mpa) is to certain volume, and density 1.192 gets Fructus Panacis Quinquefolii total saponins crude product;
B. refining: get thick Fructus Panacis Quinquefolii total saponins, last macroporous adsorbent resin AB-8 washes with water earlier to colourless, uses 20% ethanol elution instead to colourless, uses 50% ethanol elution at last, collects elutriant, be recycled to dried, must Fructus Panacis Quinquefolii total saponins product, productive rate 15%.Preparation medicine embodiment
Embodiment one: Fructus Panacis Quinquefolii total saponins 25g starch 13g
Fructus Panacis Quinquefolii total saponins and starch are mixed, incapsulate, the 0.25g/ grain is made 1000, pressing plate, and sterilization gets final product.
Embodiment two: the total 250g Sorbic Acid of Fructus Panacis Quinquefolii 10g ethanol 100ml
Get the Fructus Panacis Quinquefolii total saponins and be dissolved in the ethanol, behind the adding Sorbic Acid, be diluted to 10000nl, filter with water for pharmaceutical purposes, filling bottle, the 10ml/ bottle is made 1000 bottles, and steam sterilizing 30min gets final product.
Claims (5)
1, a kind of Fructus Panacis Quinquefolii total saponin extracts, it is characterized by light yellow to brown, Powdered, bitter, UV spectrum (methyl alcohol) has maximum absorption band at the 203nm place, HPLC spectrum demonstrates the peak more than 5, and the content of this Fructus Panacis Quinquefolii total saponin extracts accounts for the heavy 15%-20% of Fructus Panacis Quinquefolii jerky.
2, a kind of extraction of Fructus Panacis Quinquefolii total saponins, process for purification is characterized in that comprising the steps:
(1) it is a certain amount of to get Radix Panacis Quinquefolii pulp, the water that adds 3 times of amounts at normal temperatures, mechanical stirring, 100 γ pm extract 2-3 time, extract 1-3 hour at every turn;
(2) solution with each time poach gained merges, and filters filtrate for later use;
(3) above-mentioned filtrate is crossed macroporous adsorbent resin, use the 10%-20% washing with alcohol then,, abandon or adopt washing lotion, continue, collect this time elutriant with the 50%-95% ethanol elution near colourless;
(4) with behind this elutriant recovery ethanol, concentrate, drying gets the Fructus Panacis Quinquefolii total saponin extracts.
3, according to the preparation method of right 2 described Fructus Panacis Quinquefolii total saponin extracts, it is characterized in that: macroporous adsorbent resin can adopt D
101, D
4020, DA
201, AB-8, XAD-4 or D
14
4, a kind of pharmaceutical composition contains claim 1 and 2 described Fructus Panacis Quinquefolii total saponin extracts as activeconstituents.
5, according to right 4 described pharmaceutical compositions, it is characterized in that: be used for the treatment of coronary heart disease, myocardial ischemia and arrhythmia and type ii diabetes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03127613 CN1325509C (en) | 2003-07-08 | 2003-07-08 | Extract of american ginseng fruit saponin, extracting and refining method and medicinal use thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03127613 CN1325509C (en) | 2003-07-08 | 2003-07-08 | Extract of american ginseng fruit saponin, extracting and refining method and medicinal use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1482136A true CN1482136A (en) | 2004-03-17 |
| CN1325509C CN1325509C (en) | 2007-07-11 |
Family
ID=34153192
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 03127613 Expired - Lifetime CN1325509C (en) | 2003-07-08 | 2003-07-08 | Extract of american ginseng fruit saponin, extracting and refining method and medicinal use thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1325509C (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100335071C (en) * | 2004-04-27 | 2007-09-05 | 吉林省宏久生物科技股份有限公司 | Soft capsule of American ginseng fruit |
| CN100441592C (en) * | 2004-04-27 | 2008-12-10 | 吉林省宏久生物科技股份有限公司 | Method for extraction of American ginseng fruit glucoside |
| CN101940350A (en) * | 2010-07-05 | 2011-01-12 | 赵景辉 | Ginseng fruit granules with functions of sedating and soothing nerves and preparation technology thereof |
| CN102988441A (en) * | 2012-12-24 | 2013-03-27 | 李平亚 | Application of extract of American ginseng fruit |
-
2003
- 2003-07-08 CN CN 03127613 patent/CN1325509C/en not_active Expired - Lifetime
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100335071C (en) * | 2004-04-27 | 2007-09-05 | 吉林省宏久生物科技股份有限公司 | Soft capsule of American ginseng fruit |
| CN100441592C (en) * | 2004-04-27 | 2008-12-10 | 吉林省宏久生物科技股份有限公司 | Method for extraction of American ginseng fruit glucoside |
| CN101940350A (en) * | 2010-07-05 | 2011-01-12 | 赵景辉 | Ginseng fruit granules with functions of sedating and soothing nerves and preparation technology thereof |
| CN101940350B (en) * | 2010-07-05 | 2012-09-19 | 赵景辉 | Ginseng fruit granules with functions of sedating and soothing nerves and preparation technology thereof |
| CN102988441A (en) * | 2012-12-24 | 2013-03-27 | 李平亚 | Application of extract of American ginseng fruit |
| CN102988441B (en) * | 2012-12-24 | 2014-11-26 | 李平亚 | Application of extract of American ginseng fruit |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1325509C (en) | 2007-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1304039C (en) | Chinese medicine composition with functions of reducing blood-pressure, reducing-fat, anti-dizzy and calming wind, its preparing method and use | |
| CN101033245A (en) | Preparation method and application of pedunculoside | |
| CN1927331A (en) | Chinese medicine preparation for curing chronic heart failure | |
| CN1718193A (en) | Total secondary ginseng glucoside medicine composition, its prepn. method and application in preparing medicine for treating myocardial ischemia and hemorrhagic shock | |
| CN1482136A (en) | Extract of american ginseng fruit saponin, extracting and refining method and medicinal use thereof | |
| CN1857285A (en) | Capsule for treating cardiac and cerebral vascular diseases and its preparing method and application | |
| CN1291735C (en) | Chinese medicine drippling pill preparation for promoting blood circulation and removing blood stasis, promoting Qi circulation and rilieving pain | |
| CN1582952A (en) | Use of asiaticoside in preparation of medicines for diseases of cardio-cerebral blood vessels | |
| CN1733109A (en) | Soft capsule for treating coronary disease and process for preparing the same | |
| CN1817362A (en) | Chinese medicinal composition for treating heart failure and oral preparation | |
| CN1895540A (en) | Medicinal composition for treating cardiovascular disease, its making method and use | |
| CN109260205B (en) | Application of tetrandrine in preparation of medicine for resisting diabetes and hypertension | |
| CN101032534A (en) | Method of preparing jiubiying total saponins and the application thereof | |
| CN101057965A (en) | Compound traditional Chinese medicine preparation for treating cardiovascular and cerebrovascular disease | |
| CN1872241A (en) | Compound medication of valerian for treating coronary heart disease, and preparation method | |
| CN1899397A (en) | Heart activating oral disintergration tablet and its preparing method | |
| CN1899410A (en) | Medicine for treating cardiovascular disease and its preparing method and quality control method | |
| CN1843455A (en) | Pharmaceutical composition, its preparation method and usage | |
| CN1891266A (en) | Chinese medicine oral disintegrating tablet for treating angina pectoris, and its preparing method | |
| CN1233361C (en) | Traditional Chinese medicine composition for treating cardiovascular disease | |
| CN1569196A (en) | Rhodiola sacra injection and its preparation | |
| CN1857293A (en) | Medicine composition containing wild astragaloside and paeoniforin | |
| CN1245172C (en) | Function of Dangshen-Huangqi composition in treating the ischemic heart disease | |
| CN1537863A (en) | Herminium's triochistisaponine extract and its extraction refining method and its medical use | |
| CN1135996C (en) | Chinese medicine for treating coronary heart disease and angina pectoris and its preparing process |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CX01 | Expiry of patent term | ||
| CX01 | Expiry of patent term |
Granted publication date: 20070711 |
|
| CI03 | Correction of invention patent | ||
| CI03 | Correction of invention patent |
Correction item: Termination upon expiration of patent Correct: Revocation of Patent Expiration and Termination False: On July 25, 2023, the expiration and termination of the 39-volume 3001 patent Number: 30-01 Volume: 39 |